Onxeo receives EPO Intent-to-Grant Notice for New Patent strengthening European Protection of Compounds sourced from its platON™ Platform
This new patent protects in particular AsiDNA™ and its related compounds for their use in the treatment of cancer, alone or in combination with other tumor DNA-damaging agents
Paris (France), October 14, 2019 – 6:00 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the Company”), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR) in oncology, in particular against rare or resistant cancers, today announced having received a communication from the European Patent Office (EPO) informing the Company of its intent to grant a new patent strengthening the European protection of compounds sourced from its platON™ platform.
This new patent strengthens the patent portfolio around AsiDNA™, the Company’s first-in-class DNA Damage Response (DDR) inhibitor. It protects AsiDNA™ and related compounds, as such and for their therapeutic use, in particular for the treatment of cancers, alone or in combination with other agents such as radiotherapy, chemotherapy or other tumor DNA-damaging agents.
"This intent-to-grant, which was obtained very quickly after filing the application, illustrates the value of our platON™ platform through its ability to generate new patentable compounds and confirms the highly innovative nature of the products resulting from our technology to block the signaling pathways involved in the repair of tumor DNA," said Françoise Bono, Chief Scientific Officer of Onxeo.
This patent will provide a term of protection valid until mid-2031, which could be further extended until 2036 via the supplementary protection certificate (SPC) system. It completes the already robust set of 9 patent families securing the protection of AsiDNA™ and its related compounds.